LIPOSOME DRUG DELIVERY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Liposome Drug Delivery Market, By Product (Liposomal Paclitaxel, Liposomal Doxorubicin, Liposomal Amphotericin B, and Others), By Technology (Stealth Liposome Technology , Non-PEGylated Liposome Technology , and DepoFoam Liposome Technology), By Indication (Fungal Diseases, Pain Management, Cancer Therapeutics, and Others), By End User (Hospitals, Clinics, Research Laboratories, and Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

On February 13, 2024, Ipsen Biopharmaceuticals, Inc., a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved irinotecan liposome (Onivyde) for the first-line treatment of metastatic pancreatic adenocarcinoma
In March 2021, Jazz Pharmaceuticals plc, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved a revised label for Vyxeos (daunorubicin and cytarabine) to include a new indication to treat newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in pediatric patients aged one year and older. Vyxeos is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor.